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Abstract
Background: DNA microarray data are used to identify genes which could be considered prognostic markers.
However, due to the limited sample size of each study, the signatures are unstable in terms of the composing
genes and may be limited in terms of performances. It is therefore of great interest to integrate different studies,
thus increasing sample size.
Results: In the past, several studies explored the issue of microarray data merging, but the arrival of new
techniques and a focus on SVM based classification needed further investigation. We used distant metastasis
prediction based on SVM attribute selection and classification to three breast cancer data sets.
Conclusions: The results showed that breast cancer classification does not benefit from data merging, confirming
the results found by other studies with different techniques.
Background
DNA microarray technology and expression profiles are
the most suitable tools to investigate gene activity with
respect to the progress of disease. Furthermore, they are
useful for molecular classification of tumor types [1], for
revealing complexity in the intrinsic cancer subtypes
and for developing oncogenic pathway signatures as a
guide to targeted therapies [2]. In particular, breast can-
cer has been extensively studied for gene expression in
order to individualize a signature useful for molecular
classification [3] and for prognostic purposes [4,5].
However, the sample size of each study is usually too
small with respect to the number of the genes in analy-
sis to allow an accurate statistical evaluation. Therefore,
some authors used to analyze different data coming
from different experiments with the goal of increasing
sample size and thus increasing the power of the study.
This could be done in two ways: by meta-analysis [6,7],
which is the statistical analysis of a large collection of
results from individual studies for the purpose of combin-
ing their findings to reach a common result, or by data
merging, which is analyzing all the raw data coming from
different studies with similar biological questions together
[8,9].
Typically, the first transformation applied to expression
data, referred to as normalization and summarization,
removes non-biological variability between arrays [10]
and extracts gene level expression from probe intensities,
respectively.
However, the transformation procedure cannot reduce
completely the systematic differences from different data
sets. When combining data sets from different experi-
ments, non-biological experimental variation or ‘’batch
effects’’ are carried over and therefore it is inappropriate
to combine data sets without adjusting for batch effects
[11,12].
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of various data merging methods. Our strategy for biolo-
gical comparison is to use microarray data with known
phenotypes associated with specific gene sets (pathways).
In literature, several techniques have recently been pro-
posed for adjusting data for batch effects [13,14]. Many of
these methods can only be applied to two batches at a
time. In previous studies, merging data sets were applied
to develop a robust gene signature prognostic of survival
outcome discretized into two [15] or more categorical
values, or diagnostic of tumor subtypes, or predictive of
treatment response [16]. A comparison between several
techniques to merge different datasets such as ComBat,
Ratio_G, SVA, DWD, PAMR, has been carried out.
We used three breast cancer microarray data sets from
three different studies in which all the samples came from
lymph-node-negative patients who had not received adju-
vant systemic treatment. We performed three pre-proces-
sing methods: Robust Multi-Chip Average [17], frozen
RMA [18] and Quantile Normalization with Model-Based
Expression Index [19]; subsequently we applied two data
merging approaches: ComBat [20] and z-scoring standar-
dization procedure for each dataset. frozenRMA is a
recent method that performs batch effect removal inher-
ently at summarization time and which has not yet been
compared to other methods in an independent study.
ComBat has been up to now the best performing method
[21], and z-score is one of the first methods used to merge
different datasets. Chen and others [22] suggest that the
data from two experiments could be integrated for prog-
nosis analysis after data standardization. The methods
were compared from a new perspective, i.e. in terms of
SVM classification and feature selection performances.
F o rm i c r o a r r a yd a t ac l a s s i f i c a t i o nt h em e t h o d o l o g i e s
involving feature selection and classification applied to
SVM are proposed in a previous study [23].
Variation attributable to batch effects before and after
batch adjustment were identified using principal variation
component analysis (PVCA) [24]. The success of batch
effect removal was also evaluated using qualitative visua-
lization techniques such as score plot of PCA and hier-
archical clustering dendrogram.
Subsequently, the three microarray datasets, processed
in different ways, were examined for specific patterns of
pathway deregulation with respect to clinical disease out-
come. For this reason we used the most popular gene-set
analysis method, Gene Set Enrichment Analysis (GSEA)
[25].
Results
Data merging validation
We directly merged the three microarray data sets,
using the 22283 probe sets on Affymetrix HG-U133A
microarray, to form an integrated data set in seven
ways: RMA, Quantile/MBEI, RMA - ComBat, Quantile/
MBEI-ComBat, RMA - Z-Score and Quantile/MBEI - Z-
Score, frozenRMA. The integrated data set consisted of
111 samples with distant metastases and 394 samples
free of distant metastases, randomly divided into training
and testing sets but respecting the proportions of the
complete dataset. We evaluated the classification perfor-
mance using precision and recall of class 1 because of its
clinical significance. Table 1 shows the results of the clas-
sifier which demonstrated less accuracy of data merging
methods with respect to classification.
Data merging verification
Batch effects are present in microarray experiments when
data are combined from different studies. To assess the
quantity of batch effect and to compare the data merging
methods Combat, ZScore and fRMA, we performed a
novel hybrid approach known as principal variance com-
ponent analysis.
Principal Variance Component Analysis (PVCA) inte-
grates two methods: principal components analysis
(PCA) finds low dimensional linear combinations of data
with maximal variability and variance components analy-
sis (VCA) attributes and partitions variability into known
sources via a classical random effects model.
The first step is to obtain the covariance/correlation
matrix of the microarray expression data matrix. Secondly,
PCA is applied to the correlation matrix and once the
number of principal components is determined, a variance
component model is fitted separately to each of these
principal components. The variation in each principal
component is weighted by its eigenvalue from PCA, and
t h er e s u l t i n gv a l u er e p r e s e nts the overall variation
explained by that component.
The PVCA revealed that batch effects explained 22.4%
of the overall variation in the RMA data (Figure 1a) and
32,3% in the Quantile/MBEI data (Figure 1d).
After applying ComBat (Figure 1b,e) and Z-Score
(Figure 1c,f) the variation was completely eliminated. The
worst performance seemed to be that of fRMA (Figure 1g)
which showed a 24,9% threshold of variation of the batch
effects.
To assess the removal of microarray bias effect across
data sets, Principal Component Analysis (PCA) was
applied to the data sets after the application of data mer-
ging methods. The aim was to reveal intermixing of sam-
ples from different datasets before and after adjustment.
The results of these approaches (Figure 2) demonstrate
that samples referring to the same dataset cannot be
grouped after using merging methods. This trend was
respected in the RMA - ComBat data (Figure 2b), RMA -
Z-Score data (Figure 2c), MBEI - ComBat data (Figure 2e)
and MBEI - Z-Score data (Figure 2f), as shown in the
graphs of the first three principal components. Conversely
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ure 2d) and fRMA data (Figure 2g).
Again, fRMA seemed to be unable to adjust the com-
bination among the three datasets.
The results of hierarchical clustering analyses of class 1
before and after batch adjustments are presented in
Figure 3. The sample clustering showed a separation of
the three groups of samples where adjustment for batch
effects was not performed and the samples were only
summarized by RMA (Figure 3a) and MBEI (Figure 3d).
The distinct clustering of the tumor groups did not indi-
c a t eal a r g ed i f f e r e n c ei ng e n ee x p r e s s i o np a t t e r n sb u t
only a bias introduced by experimental conditions. We
clearly identified a cluster of samples performed in the
same batch without any clear biological interpretation.
After batch adjustment of the RMA dataset (Figure
3b-c) and the MBEI dataset (Figure 3e-f), the clusters
were no longer confused with the batch effects. The EB
adjustment (Figure 3b,e) has the advantage of being
robust to outliers in small sample sizes, thus no notable
difference was seen in our experimental set-up.
The GSE1121 samples clustered together more sharply
than the GSE2990 and the Foekens samples which cre-
ated overlapping clusters.
Normalized Mutual Information (NMI) [26] between
the distribution of class labels and the distribution of
Table 1 Classification performance
CB-RMA ZS-RMA
Validation Recall Precision Validation Recall Precision
LDOCV FK 0.568 0.263 LDOCV FK 0.622 0.277
GSE2990 0.5 0.286 GSE2990 0.536 0.3
GSE11121 0.63 0.315 GSE11121 0.609 0.322
Average 0.576 0.289 Average 0.596 0.301
LOOCV 0.631 0.370 LOOCV 0.512 0.317
Percentage fold 0.531 0.273 Percentage fold 0.563 0.228
Stratified perc. fold 0.677 0.198 Stratified perc. fold 0.613 0.25
RMA CB-MBEI
Validation Recall Precision Validation Recall Precision
LDOCV FK 0.622 0.304 LDOCV FK 0.649 0.282
GSE2990 0.607 0.283 GSE2990 0.571 0.314
GSE11121 0.609 0.280 GSE11121 0.652 0.341
Average 0.613 0.289 Average 0.631 0.313
LOOCV 0.613 0.289 LOOCV 0.550 0.289
Percentage fold 0.5 0.208 Percentage fold 0.625 0.282
Stratified perc. fold 0.645 0.257 Stratified perc. fold 0.692 0.237
ZS-MBEI MBEI
Validation Recall Precision Validation Recall Precision
LDOCV FK 0.73 0.297 LDOCV FK 0.486 0.290
GSE2990 0.571 0.333 GSE2990 0.643 0.290
GSE11121 0.696 0.36 GSE11121 0.522 0.414
Average 0.677 0.331 Average 0.539 0.339
LOOCV 0.550 0.279 LOOCV 0.550 0.299
Percentage fold 0.625 0.299 Percentage fold 0.625 0.282
Stratified perc. fold 0.692 0.225 Stratified perc. fold 0.808 0.28
fRMA
Validation Recall Precision
LDOCV FK 0.649 0.279
GSE2990 0.464 0.283
GSE11121 0.5 0.319
Average 0.544 0.307
LOOCV 0.512 0.308
Percentage fold 0.588 0.23
Stratified perc. fold 0.581 0.265
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after cutting the tree at a given threshold (0.5). A value
of 0.69 was observed for the RMA dataset, which
decreased to 0.23 and 0.24 after batch adjustment. The
NMI score was higher for the MBEI dataset (0.82),
again falling to 0.24 and 0.27 after batch adjustment.
For fRMA we found a score of 0.73.
Gene analysis
As previously described, two separated methods, SAM
and RFE, were used to identify differentially expressed
probes and to show the validation of RFE as feature
selection in the training step of the classification.
SAM resulted in 204, 289, 166, 197, 257, 197 and 210
differentially expressed genes for the RMA, CB-RMA,
Figure 1 PVCA results. RMA data (a), RMA - ComBat data (b), RMA - Z-Score data (c ) ,M B E Id a t a( d ) ,M B E I-C o m B a td a t a( e ) ,M B E I-Z - S c o r e
data (f), fRMA data (g).
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respectively.
Table 2 summarizes the results of shared genes
extracted by SAM and RFE - SVM.
A total of 50 common probes were found from SAM
and RFE comparison. Most probes were successfully
identify by RMA-Combat. None was found by fRMA.
These results were analyzed by fisher’s exact test to
examine the significance of overlapping between the two
gene selection algorithms. After correction for multiple
testing by the Benjamini-Hochberg standard false dis-
covery rate correction, we found that it could not be
excluded that the overlappings were derived by chance
for all but the fRMA dataset, where the test was positive
Figure 2 PCA results. RMA data (a), RMA - ComBat data (b), RMA - Z-Score data (c), MBEI data (d), MBEI - ComBat data (e), MBEI - Z-Score data
(f), fRMA data (g); FK - NCC samples in red, GSE2990 samples in green, GSE11121 samples in blue.
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Page 5 of 15Figure 3 Hierarchical clustering before and after batch adjustment. Each color marks a sample as belonging to a different batch. RMA data
(a), RMA - ComBat data (b), RMA - Z-Score data (c), MBEI data (d), MBEI - ComBat data (e), MBEI - Z-Score data (f), fRMA data (g) are shown.
Table 2 List of shared probes extracted by SAM and RFE-SVM
Probe set RMA MBEI CB RMA CB MBEI ZS RMA ZS MBEI Probe set RMA MBEI CB RMA CB MBEI ZS RMA ZS MBEI
200944_s_at - - - - x - 210084_x_at - - - x - x
201236_s_at - - x - - - 210098_s_at - - - - - x
201340_s_at x - x - x - 211776_s_at - - x - - -
201602_s_at - - x - - - 211868_x_at - - - x - x
202072_at - - - - x - 212327_at - - - - - -
202464_s_at x x x x - x 212763_at - - - - x -
202496_at - - - - x - 212840_at x - x - - -
203413_at - - x - - - 213502_x_at - x - x - -
204444_at - - - x - - 214087_s_at - x - x - -
204540_at x - x - - - 214669_x_at - - - - - x
204932_at - - - x - - 214766_s_at - - x - x -
205242_at - x - x - - 215382_x_at - - - - - -
205898_at x - - - - - 217023_x_at - - - - - -
206143_at x - - - - - 217766_s_at - - - - - x
206710_s_at - - x - - - 218009_s_at - x - - - -
207118_s_at - - - - x - 218542_at - - x - - -
207134_x_at - - - - - - 219004_s_at x - - - - -
207741_x_at - - - x - x 219115_s_at - x - x - -
208080_at - - - - x - 219148_at - - - - - -
208577_at - - - - x - 219296_at - - - - - -
208696_at - - - x - - 219306_at - - - - - -
209172_s_at - - - x - - 219438_at - - x - - -
209380_s_at x - x - x - 219743_at - - - x - x
209448_at - - x - x - 219990_at x - x - - -
209869_at - x - x - x 220177_s_at - - x - - -
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frozen RMA normalization hindered RFE from finding
biologically relevant genes, although SAM reported a
number of genes comparable to the other normalization
methods. With the “greater” alternative, every merging
technique showed a pvalue >> 0.05, showing that the
number of overlapping genes between FRE and SAM is
never greater than expected by chance.
Enrichment analysis
We explored the performance of various pre-processing
and data merging techniques by using biological path-
way-based analysis and determining whether a group of
differentially expressed genes is enriched for a particular
set.
Here, we utilized a powerful analytical method called
Gene Set Enrichment Analysis (GSEA) focusing on sev-
eral biological pathways: EGF, Stathmin, HER2, BRCA1,
Homologous Recombination, which are associated with
breast cancer progression.
The use of different methods of data merging and pre-
processing can lead to a problem of poor congruency
among datasets. To compare the ability of the different
methods we performed GSEA algorithm showing the
heat map, enrichment scores and corresponding p-
values [27].
All probe sets were pre-ranked using SNR (signal to
noise ratio) with respect to their correlation with distant
metastasis-free survival.
The signal to noise ratio (SNR) detects the expression
patterns with a maximal difference in mean expression
between two groups and minimal variation of expression
within each group.
T h eo r d e rp r o b es e tl i s tw a su s e da st h eG S E Ai n p u t
for pathway analysis.
In a heat map, expression values are represented as
colors, where the range of colors (red, pink, light blue,
dark blue) shows the range of expression values (high,
moderate, low, lowest). The light blue and dark blue
bars reflect genes that are positively associated with
DMFS (Disease Metastasis Free Survival), indicating a
higher expression in tumors without metastatic capabil-
ity. The red bars reflect genes that are negatively asso-
ciated with DMFS, indicative of higher expression in
tumors with metastatic capability. The heat map of data
sets that are pre-processed by robust multi-array average
(RMA) and MBEI and merged by fRMA are presented
in Figures 4, 5, 6.
Considering the expression level of the genes reported
in each considered pathway, it can be observed that
applying ComBat after RMA (Figure 4b) or MBEI (Fig-
ure 5b) leads to similar results to RMA (Figure 4a) and
MBEI (Figure 5a) alone, respectively. However, the Z-
Score method reported activation of different genes in
each pathway after both methods. (Figure 4c; 5c).
The heat map of RMA and MBEI data identified two
over-regulated gene sets, EGF and Stathmin Pathway,
indicative of higher expression in tumors with meta-
static capability and three up-regulated gene sets,
Homologous Recombination, BRCA1 and HER2 path-
way, indicating a higher expression in tumors without
metastasis.
G e n eS e tE n r i c h m e n tA n a l y s i sc o m p u t e sa ne n r i c h -
ment score (ES) for a given gene set which reflects the
degree to which a gene set is over-represented at the
extremes of the entire ranked list of genes.
Figure 4 Heat map of RMA pre-processed datasets. RMA data (a), RMA - ComBat data (b), RMA - Z-Score data (c).
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Page 7 of 15Figure 5 Heat map of MBEI pre-processed datasets. MBEI data (a), MBEI - ComBat data (b), MBEI - Z-Score data (c).
Figure 6 Heat map of fRMA merged datasets.
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of ranked list; a negative ES suggests gene set enrich-
ment at the bottom of the ranked list.
The nominal p-value estimates the statistical signifi-
cance of the enrichment score for a single gene set.
We found (Tables 3, 4) that both RMA and MBEI
detected Homologous Recombination as the most signif-
icant gene set, however, the statistical significance of
RMA of this gene set was much greater, p= 0.0082
(RMA) p = 0.0073 (CBRMA) p = 0.0019(ZSCORE) ver-
sus p = 0.0057 (MBEI) p = 0.0020 (CBMBEI) p = 0.3836
(ZSMBEI).
Overall, GSEA with RMA normalization identified two
gene sets, Homologous Recombination and BRCA1
pathway, as statistically significant at p<0.05 whereas
GSEA with MBEI normalization detected Homologous
Recombination and EGF pathway with the same p-value.
For all gene sets, p-values obtained by RMA normali-
zation were generally smaller than the p-values of corre-
sponding gene sets obtained by MBEI normalization.
With Combat data, GSEA identified, although with
higher significance, the same gene sets derived from
RMA or MBEI data alone.
Comparison of different data merging techniques con-
firmed that ZScore shows more variation than MBEI or
RMA data alone.
fRMA revealed different gene sets regulated with a
higher p-value than ZScore and Combat. A comparative
representation of the different evaluation and verifica-
tion methods is presented in Figure 7. For the classifica-
tion analysis an F-measure with beta equal to 2 is
reported. This measure gives a recall higher than
precision and is more suitable for a summarization of
the classifier performances in the clinical context. For
the PVCA analysis the weight of the batch effect com-
ponent is reported. Figure 7 also presents a complement
to 1 of the NMI score for the clustering analysis, the
number of relevant genes found by SAM and the -log10
(pvalue) for the negative effect of the merging algorithm
on the ability of RFE to select biologically relevant
genes. The number of enriched pathways found by
GSEA is shown at the end.
Discussion
In this study we have presented the results of the classi-
fication of breast cancer microarray data, with respect to
the event of distant metastasis free survival in terms of
recall and precision. The results show very low classifi-
cation performances. This is explained in part by het-
erogeneity of the data in terms of tumor grade, tumor
size, histopathological tumor type and progesterone and
estrogen receptor that might negatively influence the
prediction. In the past, different classifiers were built for
patients showing different values for these features with
successful results [28].
The F-2 scores in Figure 7a show that for both z-score
and Combat merging procedures the results of classifi-
cation with LDO validation are enhanced only when
applied to the MBEI summarization.
Z-score performed better than Combat with both
summarization techniques and the worst results were
achieved by fRMA.
The LDO validation is representative of a clinical
application where batches of patients are analyzed after
Table 3 Application of GSEA to the different RMA and fRMA pre-processing and data merging methods
Gene set RMA CB RMA ZS RMA fRMA
ES p-value ES p-value ES p-value ES p-value
EGF pathway -0.4229 0.1285 -0.4542 0.0923 -0.4127 -0.3109 -0.3731 0.3145
Stathmin pathway -0.4307 0.4712 -0.4281 0.5079 -0.2711 -0.6063 -0.2844 0.9051
Homologous recombination 0.6766 0.0082 0.6956 0.0073 0.6962 0.0019 0.3378 0.5750
BRCA1 pathway 0.2974 0.0278 0.3017 0.0403 0.2982 0.1353 -0.1768 0.8875
HER2 pathway 0.3388 0.5658 0.3475 0.5507 0.4504 0.0730 -0.3795 0.4612
Table 4 Application of GSEA to the MBEI pre-processed datasets
Gene set MBEI CB MBEI ZS MBEI
ES p-value ES p-value ES p-value
EGF pathway -0.4793 0.0451 -0.4387 0.0647 -0.2616 0.6179
Stathmin pathway -0.3323 0.5778 -0.3492 0.5848 -0.3551 0.5186
Homologous recombination 0.6516 0.0057 0.6533 0.0020 -0.3582 0.3836
BRCA1 pathway 0.3067 0.0746 0.3032 0.0763 0.3112 0.1509
HER2 pathway 0.3434 0.5098 0.3747 0.3727 0.38071 0.2003
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context of practical interest the merged datasets show
some advantages compared to non-merged datasets.
Figure 7b shows however that these results are com-
parable to those of non- merged MBEI datasets with
stratified percentage folding, where obviously the classi-
fier cannot benefit from the higher number of samples
coming from different batches and the results could
have been even better if the classifier had been built on
a single batch. In this case the classifier probably
Figure 7 Overview of results. An overview of the results of the data merging evaluation methods used in this study for SVM classification with
leave-dataset-out (a) and stratified percentage folding (b), PVCA analysis (c), clustering (d), SAM (e), RFE-SAM overlapping (f) and enrichment
analysis (g). The bars in each plot refers to RMA (red), CB-RMA (yellow), ZS-RMA (green), MBEI (blue), CB-MBEI (orange), ZS-MBEI (purple) and
fRMA (pink) respectively.
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Thus we can conclude that the SVM classifier could not
benefit from the merging of different batches and the
increasing number of samples.
The difference between Stratified Percentage Fold and
weighted LDOCV average is very sharp in the MBEI
pre-processed datasets showing that this method gets
greater benefits from the merging algorithms. The com-
parison within the RMA processed datasets shows that
the non-merged dataset has even higher performances
than the ComBat and Z-score merged ones in stratified
percentage folding.
However, the merging procedure achieved some results,
as shown by the PVCA and Clustering analysis, where
both z-score and Combat datasets behaved better than
non- merged ones. Combat and z-score did not show
sharp differences with these techniques. When comparing
the differences in the SVM versus PVCA/Clustering
results, we can conclude that the merging algorithms are
an effective tool, but should be handled with care when it
comes to the next algorithm in the workflow pipeline.
fRMA showed performances comparable to non-
merged datasets also in the PVCA/Clustering case and
our findings exclude it from being a good data merging
algorithm even when compared with the simplest strat-
egy of z-scoring.
A comparative study of performances of Recursive
Feature Elimination (RFE) with SAM has been given as
an additional evaluation tool for the validation of RFE as
feature selection.
Also in this case we found an exception: SAM did not
suffer from the fRMA normalization and reported a
number of differentially expressed genes compared to
the other techniques. Again in this case Combat outper-
formed z-score with a number of genes almost double.
In the same step of gene selection, RFE showed results
markedly different from SAM, and the number of com-
mon genes, equal to zero, is not derived from chance:
fRMA hindered RFE from finding biologically relevant
genes.
The biological meanings of gene expression have been
also analyzed in terms of enrichment analysis.
Our objectives tested predefined gene sets for their
association with breast cancer progression, assuming
that gene expression changes can be identified at the
level of co regulated gene sets rather than individual
genes.
The application of gene set analysis by GSEA was also
useful in finding common biological pathway changes
and in comparing different preprocessing and data mer-
ging methods.
GSEA detected three gene sets, Homologous Recom-
bination, BRCA1 and HER2 pathway, as significantly
up-regulated versus two gene sets, EGF and Stathmin
Pathway, which were over-regulated; although in many
cases the same gene sets were identified as significant by
various programs, in a direct comparison across MBEI
and RMA normalization using breast cancer datasets,
the p-values of RMA were lower than the respective p
values obtained by MBEI (Table 4), indicating that RMA
is more statistically sensitive than MBEI for these gene
sets.
Again, fRMA found gene sets with lower significance
than the others and Combat outperformed z-score,
although the latter showed better results in terms of
classification performances. In terms of pathway enrich-
ment, the results of Combat merging are comparable to
those of non-merged datasets.
Overall, this study confirms the previous studies that
did not show benefits of survival prediction with merged
datasets as compared to individual data sets using linear
methods [29]. It also confirms that Combat outper-
formed the other programs and the different pre-proces-
sing methods (MBEI and RMA) did not show significant
variation giving rise to improvement of prediction. [21].
Furthermore, the analysis of gene expression level in
specific pathways confirmed the better performance of
ComBat with respect to Z-Score, and focusing on
PVCA, fRMA was inaccurate in removing the batch
effect from the data. This is evident when observing the
graphical representation of data after PCAnalysis, hier-
archical clustering and PVCA.
Conclusions
The present study showed the difficulty of merging data
from different datasets, even if they come from the
same type of chip, due to the low accuracy even when
using different approaches. This suggests that because of
the low recall and precision of all methods, data mer-
ging does not seem to be the elective approach to com-
bine samples in array analysis. Thus a better way to
improve accurate signature from microarray datasets is
to apply a meta-analysis rather than merging all raw
data or developing algorithms that can leverage the
effect of data merging, since we have demonstrated that
it is algorithm-dependent.
Methods
Dataset and preprocessing methods
We applied pre-processing and data merging techniques
to three breast cancer data sets: GSE11121, GSE2990
(Gene Expression Omnibus) and a dataset used by Foe-
kens et al. in [30], containing respectively 200, 125 and
180 samples from the same Affymetrix GeneChip
Human Genome U133A platform. All of the patients in
the data sets had lymphonode-negative tumors and did
not receive adjuvant systemic treatment. The design of
the study is reported in Figure 8.
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array data to compute expression values from input
CEL files: Robust Multi-array Average (RMA), Quantile
normalization - Model-Based Expression Index (MBEI)
and frozenRMA. This last method estimates batch effect
directly from probe intensities. The other methods were
integrated in an independent manner with two data
merging techniques: 1) ComBat 2) Z-score. All compu-
tations were done using the free statistical software
package R and DNA-Chip Analyzer (dChip).
Processing Affymetrix expression arrays usually con-
sists of three steps: background adjustment, normaliza-
tion and summarization and, in this study, the data sets
were processed in three ways (Table 5).
Before proceeding to the next analysis, it is necessary
to detect and remove the batch effects. Here, the term
“batch effect” refers to experimental variations of data-
sets generated by different labs.
An Empirical Bayes method, called Combating Batch
Effects when Combining Batches of Gene Expression
Microarray Data (ComBat) and Z-Score were used to
adjust the systematic difference of differently normalized
data generated by the three different labs. The algorithm
of Johnson et al. was implemented into the software
package ComBat, which includes two empirical Bayes
frameworks, one with parametric and one with non-
parametric approach. With this algorithm, location and
scale model parameters are specifically estimated by
pooling information across genes in each batch to adjust
for the batch effect parameter estimates toward the
overall mean of the batch estimates.
Each data set was alternatively standardized using a
simple z-score transformation method and combined for
analysis. In contrast to classic pre-processing and data
merging techniques, we applied another pre-processing
algorithm, Frozen Robust Multiarray Analysis (fRMA)
Figure 8 Study workflow.
Table 5 Pre-processing methods
Preprocessing
Method Background correction Normalization Summarization
RMA Global correction from posterior mean given
the observed PM
Quantile: intensities quantiles
Average
Linear model including array and probe effects fitting
by median polish
Quantile
-MBEI
- Quantile: baseline intensities Model assuming multiplicative probe effect and
additive error
FrozenRMA RMA-like Quantile: reference
distribution intensity
RMA-like including batch effect in the model
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then combine the data for analysis. fRMA without
further adjustment for batch effects is similar to RMA
when the data are analyzed as a single batch.
This procedure led to seven differently-merged data-
sets: RMA without merging (RMA), RMA data merged
by Combat (CB-RMA) and by z-score (ZS-RMA), MBEI
without merging (MBEI), MBEI data merged by Combat
(CB-MBEI) and by z-score (ZS-MBEI) and fRMA data
(fRMA).
Classification
After these steps, the above procedures were analyzed to
extract a gene signature, in order to associate it with
distant-metastasis-free survival (dmfs) discretized into
two values (0,1). The datasets were unbalanced towards
class 0, but from a clinical stand point, the cost of false
negatives is higher than false positives: patients that
should receive treatment may be neglected and not
receive treatment. For this reason, the class 0 set were
down-sampled until half spread.
The training step applies a SVM based Recursive Feature
Elimination (RFE) method [31,32] for the selection of
genes using an iterative procedure which ranks features
and discards the worst one, after sub sampling of the data-
set to make the distribution size of the two classes equal.
This model, composed of 400 gene expression levels, was
then used for the training of a linear support vector
machine, a classifier widely used in bioinformatics for its
features [33]. The number of genes was set to 400 after a
comparison of results for each dataset. The classifier per-
formances were optimal around this value and relatively
insensitive to small variations in the number of features.
The next step consisted of testing the dataset that had not
been used on the samples to train the classifier. In this
study, we used two performance measures of the classifier:
recall (sensitivity) and precision.
Validation methods
The models were validated using Leave-One-Out Cross
Validation (LOOCV), Leave-Dataset-Out Cross Validation
(LDOCV), Percentage Fold and Stratified Percentage Fold.
The Leave-One-Out (or LOO) is a simple cross-validation.
Each learning set is created by using all the samples except
one, the test set being the sample left out.
Leave-one-out cross validation is used in the field of
machine learning to determine how accurately a learning
algorithm will be able to predict data that it was not
trained on. It creates all the possible training/test sets by
using a single observation from the original sample as the
testing data, and the remaining observations as the train-
ing data. LDOCV is very similar to LOOCV but it consid-
ers the single dataset rather than samples. Percentage Fold
randomly divides the merged data set into training and
testing sets, 66% and 34% respectively; the Stratified Per-
centage Fold splits each dataset by preserving the same
percentage for training and testing sets.
Principal variation component analysis (PVCA) and
hierarchical clustering
In this study we utilized PVCA to compute non biologi-
cal experimental variation or “batch effects” carried over
when we combined the three data sets from different
experiments. The approach utilizes two data analysis
methods: first, principal component analysis (PCA) is
used to efficiently reduce data dimension while main-
taining the majority of the variability in the data, and
variance component analysis (VCA) fits a mixed linear
model using factors of interest as random (or batch)
effects and other variables (or covariates) to estimate
and partition the total variability.
Average linkage hierarchical cluster analysis was carried
out using Mev software with a modified Pearson correla-
tion as a similarity metric. The clustering on each dataset
was performed using all the genes in the platform.
Gene and enrichment analysis
The genes that exhibited little variation in their profile
and which were not of interest were removed from data
for the subsequent pathway analysis. Filtered datasets
were also analyzed for statistically significant genes
using the Significance Analysis of Microarray (SAM)
algorithm [34]. SAM is a statistical technique for deter-
mining whether changes in gene expression are statisti-
cally significant. The analysis was performed using MeV
(MultiExperimentViewer) [35] to search for genes that
correlated with distant metastasis.
A comparative study of performances of Recursive
Feature Elimination (RFE) with SAM was carried out as
an additional evaluation tool.
For further validation of different data merging and
processing technique comparison, we analyzed specific
pathways associated with breast cancer progression: EGF,
Stathmin, HER2, BRCA1 and Homologous Recombina-
tion. The pathway database was compiled from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) and Bio-
carta. The GSEA algorithm, an established method in
pathway enrichment analysis, was used. Enrichment ana-
lysis is an automated statistical technique to analyze and
interpret large gene lists using a priori knowledge. The
strength of gene regulation information is an important
component of cancer classifiers, which have been proven
to be able to leverage such information [36]. A data mer-
ging algorithm that maximizes the regulation information
contained in the dataset is also suitable for providing an
optimal substrate for classification.
The genes can be ordered in a rank list, according to
their differential expression between the classes, and the
Bevilacqua et al. BMC Bioinformatics 2012, 13(Suppl 7):S9
http://www.biomedcentral.com/1471-2105/13/S7/S9
Page 13 of 15goal of GSEA algorithm is to determine whether the
members of specific pathways are randomly distributed
throughout the ranked list or primarily found at the top
or bottom. If a statistically significant number of genes
from a specific pathway is present in the gene list, it
may indicate that the biological pathway plays a role in
the biological condition under study.
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